476620-22-1

Basic information

• Product Name: 3-PYRAZOL-1-YL-PHENYLBORONIC ACID
• Synonyms: [3-(1H-PYRAZOL-1-YL)PHENYL]BORONIC ACID;3-PYRAZOL-1-YL-PHENYLBORONIC ACID;CHEMBRDG-BB 4009715;boronic acid, [3-(1H-pyrazol-1-yl)phenyl]-;[3-(1H-pyrazol-1-yl)phenyl]boronic acid(SALTDATA: FREE);Boronic acid, B-[3-(1H-pyrazol-1-yl)phenyl]-;[3-(1-pyrazolyl)phenyl]boronic acid
• CAS NO: 476620-22-1
• Molecular Formula: C₉H₉BN₂O₂
• Molecular Weight: 187.99
• Mol File: 476620-22-1.mol

Chemical Properties

• Boiling Point: 402.663°C at 760 mmHg
• Flash Point: 197.324°C
• Appearance: /
• Density: 1.209g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-PYRAZOL-1-YL-PHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRAZOL-1-YL-PHENYLBORONIC ACID(476620-22-1)
• EPA Substance Registry System: 3-PYRAZOL-1-YL-PHENYLBORONIC ACID(476620-22-1)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 476620-22-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
3-Pyrazol-1-yl-phenylboronic acid is used as a critical intermediate for the synthesis of bioactive molecules and complex compounds. Its involvement in Suzuki-Miyaura cross-coupling reactions allows for the creation of a wide range of organic compounds with potential applications in various fields.
Used in Pharmaceutical Industry:
3-Pyrazol-1-yl-phenylboronic acid is used as a key building block in the development of new pharmaceuticals. Its unique structure and reactivity enable the creation of novel drug candidates with potential therapeutic applications.
Used in Material Science:
3-Pyrazol-1-yl-phenylboronic acid is used as a component in the synthesis of advanced materials, such as organic semiconductors and catalysts. Its versatility in organic chemistry allows for the design and creation of materials with tailored properties for specific applications.

InChI:InChI=1/C9H9BN2O2/c13-10(14)8-3-1-4-9(7-8)12-6-2-5-11-12/h1-7,13-14H

Downstream Products

• 1603135-69-8 C₁₈H₁₈ClN₅O₂S₂ 
• 1107655-20-8 1-(3-piperidin-1-yl-propyl)-4-[3-(3-pyrazol-1-yl-phenyl)-imidazo[1,2-b]pyridazin-7-yl]-1H-pyridin-2-one 
• 1225280-35-2 6-[3-(1H-pyrazol-1-yl)phenyl]quinoxaline 
• 1146614-35-8 7-chloro-3-(3-pyrazol-1-yl-phenyl)-imidazo[1,2-a]pyridine 
• 1146613-28-6 N-methyl-3-[3-(3-pyrazol-1-yl-phenyl)-imidazo[1,2-a]pyridin-7-yl]-benzamide 
• 919341-10-9 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[3-(1H-pyrazol-1-yl)phenyl]-1H-indole-7-carboxamide 
• 905580-16-7 [(3aR,4R,6R,6aR)-2,2-dimethyl-6-(6-[3-(1H-pyrazol-1-yl)phenyl]-9H-purin-9-yl)-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]methyl acetate 

Relevant articles and documents

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.